

Research Article

Mesenchymal Stem Cell Therapy for Azoospermia: Navigating Differentiation Challenges and Charting Future Frontiers in Male Fertility Treatment

Farhad Rahmanifar*

Department of Basic Sciences, Shiraz University, Shiraz, Iran

ORCID:

Farhad Rahmanifar: <https://orcid.org/0000-0001-9585-7266>

Abstract

This minireview explores the current landscape of stem cell therapy for azoospermia, focusing on the potential and challenges associated with Mesenchymal Stem Cells (MSCs). The discussion encompasses the precise regulation of MSC differentiation, safety considerations, and ethical implications. Recent advancements in optimizing differentiation protocols, improving engraftment efficiency, and ongoing clinical trials are highlighted. Despite the hurdles, MSCs emerge as a promising avenue for male infertility treatment. The conclusion emphasizes the necessity for continued research and clinical trials to unlock the full potential of MSC therapy in addressing the complexities of azoospermia.

Corresponding Author: Farhad Rahmanifar; email: f.rahmanifar@yahoo.com

Received: October 9 2023

Accepted: January 10 2024

Published: March 14 2024

Production and Hosting by Knowledge E

© Farhad Rahmanifar. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Keywords: azoospermia, stem cell therapy, mesenchymal stem cells, differentiation, safety, ethical considerations

1. Introduction

Stem cell therapy for azoospermia holds great promise in addressing male infertility, specifically, the condition where there is a complete absence of sperm in the ejaculate [1]. This innovative approach aims to restore spermatogenesis by utilizing the regenerative potential of stem cells [2].

Several studies have explored the use of different types of stem cells, such as mesenchymal stem cells (MSCs) [3] and spermatogonial stem cells (SSCs) [4], in the treatment of azoospermia. MSCs, known for their differentiation capabilities, have shown potential in promoting the regeneration of damaged testicular tissue [5]. SSCs, on the other hand, hold the key to initiating the spermatogenesis process [6].

However, despite the excitement surrounding stem cell therapy, there are significant challenges that must be addressed. One major hurdle is the precise regulation of stem cell differentiation into functional sperm cells [7]. Ensuring that the differentiated cells

 OPEN ACCESS

contribute to sperm production without forming tumors or causing unwanted side effects is a complex task [8].

Additionally, ethical considerations and safety issues remain paramount. Rigorous research is necessary to establish the long-term safety and efficacy of stem cell therapies for azoospermia [9]. Ethical concerns arise due to the use of human embryonic stem cells and the potential for germ cell manipulation [10].

Furthermore, the heterogeneity of azoospermia poses a challenge, as different subtypes may require tailored approaches [11]. Patient selection and individualized treatment strategies are crucial for success.

This minireview aims to provide a comprehensive overview of the role of MSCs in the context of azoospermia treatment. By exploring the differentiation capabilities of MSCs and their potential applications in regenerating damaged testicular tissue, this section sets the stage for a nuanced discussion on the challenges, safety considerations, and ethical dimensions surrounding MSC therapy. Ultimately, the goal is to highlight the pivotal role of MSCs in reshaping the landscape of male fertility treatment and to underscore the ongoing efforts in research and clinical exploration within this promising field.

2. Precise Regulation of Stem Cell Differentiation

Achieving precise regulation of stem cell differentiation, particularly when targeting the development of functional sperm cells, is a scientific endeavor rife with challenges [12]. The potential benefits are immense, particularly in the context of azoospermia treatment, where MSCs have demonstrated the ability to contribute to the regeneration of damaged testicular tissue [3].

The unique strength of MSCs lies in their pluripotent nature, allowing them to differentiate into various cell types, including those essential for spermatogenesis [13]. This inherent capability positions MSCs as a promising avenue for therapeutic interventions aimed at restoring fertility in individuals suffering from azoospermia [3]. However, the path to harnessing this potential is fraught with obstacles.

One of the central challenges in steering MSCs toward the specific differentiation required for sperm cell development is the need for precise regulation [14]. The delicate balance required to orchestrate the transformation of these cells into functional sperm is a complex dance of molecular signals and genetic cues [15]. Achieving this precision is paramount to ensure that the resulting sperm cells are fully functional and capable of fulfilling their reproductive role [16].

Moreover, the risk of undesired outcomes looms large in the realm of stem cell therapy [16]. A particularly concerning consequence is the potential for uncontrolled differentiation leading to tumorigenesis [17]. The very mechanisms that drive stem cells to differentiate into specialized cell types can, under certain conditions, spiral out of control, giving rise to the formation of tumors [3]. This is a significant hurdle that demands meticulous exploration and understanding.

To mitigate the risk of tumorigenesis, researchers must delve into the intricate molecular mechanisms that govern stem cell differentiation [18]. Unraveling the signaling pathways and genetic switches that dictate the fate of MSCs is crucial for designing interventions that not only promote spermatogenesis but also circumvent the potential pitfalls of aberrant cell growth.

In this quest for precision, advancements in molecular biology, genomics, and bioinformatics play pivotal roles. Cutting-edge technologies enable scientists to scrutinize the cellular landscape with unprecedented detail, deciphering the intricate networks that guide stem cell fate. This knowledge forms the foundation for developing targeted therapies that can coax MSCs into differentiating with the precision required for successful sperm cell formation.

In conclusion, while the potential of MSCs in treating azoospermia is promising, the journey towards harnessing their full capabilities is intricate and demanding. The challenges lie not only in promoting differentiation but also in avoiding the pitfalls of uncontrolled growth, such as tumor formation. A comprehensive understanding of the molecular underpinnings of stem cell fate is imperative to navigate these challenges and pave the way for precise regulation of differentiation—a crucial step in unlocking the therapeutic potential of stem cells in the realm of reproductive medicine.

3. Safety and Long-term Efficacy

The pursuit of stem cell therapies, particularly those centered around MSCs, demands an unwavering commitment to ensure safety and long-term efficacy [19]. Rigorous research serves as the linchpin in this endeavor, acting as a crucial checkpoint to evaluate the potential risks and benefits associated with these innovative treatments.

The necessity of thorough research becomes apparent when considering the intricacies of MSC-based therapies. While these cells exhibit remarkable regenerative potential, their introduction into the body for therapeutic purposes requires a nuanced understanding of their behavior. Rigorous investigation is essential not only to unveil the immediate effects of the treatment but also to delve into the long-term repercussions.

Existing studies have provided valuable insights into the safety and efficacy of MSC-based therapies, yet notable findings underscore the need for continued scrutiny [20]. Some studies have reported positive outcomes, showcasing the regenerative prowess of MSCs in various medical conditions [17]. However, a comprehensive understanding requires a closer examination of potential adverse effects, including immunological responses, tumorigenic risks, and unintended consequences.

Longitudinal studies play a pivotal role in this comprehensive evaluation [21]. Tracking the fate of MSCs post-transplantation is essential to discern whether these cells integrate seamlessly into the host tissues or if there are lingering concerns regarding their behavior [22]. This extended observation period is crucial for uncovering any delayed or latent effects that might not be immediately apparent.

In the pursuit of safety, researchers must not only focus on the intended therapeutic effects but also be vigilant about potential off-target consequences [23]. Unraveling the molecular mechanisms governing the interactions between MSCs and the host environment is paramount [24]. This knowledge not only aids in understanding the safety profile but also provides insights into refining the therapeutic approach for enhanced efficacy.

Despite the strides made in stem cell research, notable gaps in knowledge persist. The intricate interplay between MSCs and the immune system, the potential for immunogenic reactions, and the long-term integration of these cells into diverse tissue types are areas that warrant further exploration [25]. Bridging these knowledge gaps is essential to fortify the foundation of stem cell therapies, ensuring that these treatments stand the test of time in terms of safety and efficacy.

As the field advances, embracing emerging technologies and methodologies becomes imperative. Cutting-edge tools in genomics, proteomics, and imaging techniques offer unprecedented avenues to unravel the complexities of MSC behavior within the intricate milieu of the human body [26]. Integrating these technological advancements into research protocols enhances the precision and depth of safety assessments.

In conclusion, the quest for safe and effective stem cell therapies, particularly those involving MSCs, hinges on rigorous research. Longitudinal studies, careful scrutiny of existing findings, and a proactive approach to address the knowledge gaps are vital components of this ongoing exploration. By embracing a comprehensive and vigilant research framework, scientists can pave the way for the responsible and successful integration of stem cell therapies into the landscape of medical treatments.

4. Ethical Considerations

Delving into the realm of stem cell therapies, particularly those involving MSCs, necessitates a profound examination of ethical considerations [10]. The source of these cells, ranging from embryonic tissues to other origins, raises significant ethical concerns that must be navigated with care [27]. Balancing the pursuit of scientific progress with adherence to ethical standards is paramount for the responsible development and application of MSC-based therapies.

Germ cell manipulation, another facet of stem cell research, introduces a unique set of ethical considerations [28]. The ability to manipulate germ cells, which are involved in the transmission of genetic information to future generations, raises concerns about the potential for unintended consequences and ethical boundaries [29]. Ethical frameworks must be established to guide the responsible manipulation of germ cells, considering the far-reaching implications on both individuals, and society as a whole.

The importance of adhering to ethical standards in the development and application of stem cell therapies cannot be overstated. Beyond the scientific advancements, ethical considerations serve as a compass, guiding researchers and practitioners through the complex ethical terrain associated with stem cell research. Ethical guidelines not only safeguard the rights and well-being of individuals involved in clinical trials but also uphold the broader societal values and principles that underpin responsible scientific conduct.

Respecting autonomy, informed consent, and transparency are foundational pillars of ethical standards in stem cell research [29]. Ensuring that individuals are fully informed about the nature of the treatments, potential risks, and benefits empowers them to make autonomous decisions regarding their participation in clinical trials [30]. Ethical oversight committees play a crucial role in evaluating research proposals, ensuring that ethical principles are upheld, and the potential benefits outweigh the ethical concerns [31].

As the field of stem cell research evolves, continuous dialogue and reflection on ethical considerations are essential. Ethical frameworks must adapt to the dynamic landscape of scientific discoveries and emerging technologies. Public engagement and open discussions about the ethical implications of stem cell therapies foster a collective understanding and consensus on acceptable ethical boundaries.

In conclusion, while MSCs hold immense promise in the realm of regenerative medicine, ethical considerations are inseparable from their development and application. From the use of human embryonic stem cells to germ cell manipulation, each

avenue demands careful ethical scrutiny. Upholding ethical standards is not just a moral imperative, it is a foundational requirement for the responsible advancement of stem cell therapies, ensuring that scientific progress aligns harmoniously with the ethical values that define our society.

5. Patient Heterogeneity and Individualized Treatment

Navigating the landscape of azoospermia, characterized by its inherent heterogeneity, poses a formidable challenge in the realm of stem cell therapy [3]. The diverse underlying causes of this condition demand a nuanced approach, highlighting the imperative need for tailored treatment strategies [32]. Addressing the complexities of patient heterogeneity is a pivotal step in harnessing the full potential of MSC therapy for azoospermia [33].

Azoospermia, with its multifaceted origins ranging from genetic factors to environmental influences, requires a thorough understanding of the specific conditions driving testicular damage in individual patients [32]. The challenge lies not only in recognizing the heterogeneity but also in tailoring treatment approaches to address the unique aspects of each case. One size does not fit all in the realm of azoospermia, necessitating a departure from generalized therapeutic strategies [34].

Personalized medicine emerges as a beacon of hope in this scenario [35]. By customizing MSC therapy to the distinct profiles of individual patients, the potential for success is magnified [36]. Patient-specific considerations, such as the type and severity of testicular damage, genetic predispositions, and environmental factors, become pivotal in crafting a treatment regimen that aligns seamlessly with the intricacies of each case [37].

The first step towards personalized strategies involves comprehensive diagnostic approaches. Precision in identifying the root causes and understanding the specific nature of testicular damage sets the stage for tailoring therapeutic interventions [38]. Advanced imaging techniques, genetic profiling, and detailed clinical assessments contribute to a holistic understanding of the patient's condition, paving the way for targeted therapeutic decisions [39].

The heterogeneity of azoospermia also extends to the diverse responses' individuals may exhibit to stem cell therapy [3]. Personalized treatment approaches allow for the adaptation of interventions based on the unique characteristics and responses of each patient. This flexibility is vital in optimizing the therapeutic outcome, as it

acknowledges the variability in patient responses and the need for dynamic adjustments to the treatment plan.

Moreover, a personalized approach aligns with the principles of precision medicine, optimizing the benefits of MSC therapy while minimizing potential risks [40]. Tailoring treatment strategies to the individual's specific needs enhances the likelihood of successful outcomes and reduces the likelihood of adverse effects, creating a more patient-centric and ethically sound therapeutic paradigm [41].

In conclusion, the heterogeneity of azoospermia underscores the necessity for personalized treatment approaches in the realm of stem cell therapy. By recognizing and addressing the diverse underlying causes of this condition, tailored interventions can be designed to optimize therapeutic efficacy. Personalized strategies not only acknowledge the unique nature of each patient's condition but also pave the way for a more nuanced, adaptive, and successful approach to MSC therapy in the pursuit of treating azoospermia.

6. Conclusion

In navigating the intricate challenges of stem cell therapy for azoospermia, including differentiation precision, safety, and ethical considerations, continued research and clinical trials are imperative. Mesenchymal stem cells, while facing hurdles, stand as a promising frontier in revolutionizing male infertility treatments. Dedication to unraveling complexities ensures that the full potential of MSC therapy is realized, shaping the future of azoospermia interventions.

References

- [1] Wu JX, Xia T, She LP, Lin S, Luo XM. Stem cell therapies for human infertility: Advantages and challenges. *Cell Transplant*. 2022;31:9636897221083252.
- [2] Qian C, Meng Q, Lu J, Zhang L, Li H, Huang B. Human amnion mesenchymal stem cells restore spermatogenesis in mice with busulfan-induced testis toxicity by inhibiting apoptosis and oxidative stress. *Stem Cell Res Ther*. 2020;11(1):290.
- [3] Zhankina R, Baghban N, Askarov M, Saipiyeva D, Ibragimov A, Kadirova B, et al. Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: A systemic review. *Stem Cell Res Ther*. 2021;12(1):229.
- [4] Abdelaal NE, Tanga BM, Abdelgawad M, Allam S, Fathi M, Saadeldin IM, et al. Cellular

- therapy via spermatogonial stem cells for treating impaired spermatogenesis, non-obstructive azoospermia. *Cells*. 2021;10(7).
- [5] Tamadon A, Mehrabani D, Rahmanifar F, Jahromi AR, Panahi M, Zare S, et al. Induction of spermatogenesis by bone marrow-derived mesenchymal stem cells in busulfan-induced azoospermia in hamster. *Int J Stem Cells*. 2015;8(2):134-45.
- [6] Ibtisham F, Honaramooz A. Spermatogonial stem cells for in vitro spermatogenesis and in vivo restoration of fertility. *Cells*. 2020;9(3).
- [7] Cho IK, Easley CA. Recent developments in in vitro spermatogenesis and future directions. *Reproductive Medicine*. 2023;4(3):215-32.
- [8] Chao HH, Zhang Y, Dong PY, Gurunathan S, Zhang XF. Comprehensive review on the positive and negative effects of various important regulators on male spermatogenesis and fertility. *Front Nutr*. 2022;9:1063510.
- [9] Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. Stem cell-based therapy for human diseases. *Signal Transduct Target Ther*. 2022;7(1):272.
- [10] Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and safety issues of stem cell-based therapy. *Int J Med Sci*. 2018;15(1):36-45.
- [11] Cervan-Martin M, Tuttelmann F, Lopes AM, Bossini-Castillo L, Rivera-Egea R, Garrido N, et al. Immune and spermatogenesis-related loci are involved in the development of extreme patterns of male infertility. *Commun Biol*. 2022;5(1):1220.
- [12] Zakrzewski W, Dobrzynski M, Szymonowicz M, Rybak Z. Stem cells: Past, present, and future. *Stem Cell Res Ther*. 2019;10(1):68.
- [13] Fayezi S, Fayyazpour P, Norouzi Z, Mehdizadeh A. Strategies for mammalian mesenchymal stem cells differentiation into primordial germ cell-like cells: A review. *Cell J*. 2022;24(8):434-41.
- [14] Teves ME, Roldan ERS, Krapf D, Strauss JF, III, Bhagat V, Sapao P. Sperm differentiation: The role of trafficking of proteins. *Int J Mol Sci*. 2020;21(10).
- [15] Makela JA, Hobbs RM. Molecular regulation of spermatogonial stem cell renewal and differentiation. *Reproduction*. 2019;158(5):R169-R87.
- [16] Tanga BM, Qamar AY, Raza S, Bang S, Fang X, Yoon K, et al. Semen evaluation: Methodological advancements in sperm quality-specific fertility assessment - A review. *Anim Biosci*. 2021;34(8):1253-70.
- [17] Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. *Cells*. 2019;8(8).
- [18] Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. *Cell Mol Life Sci*. 2020;77(14):2771-94.

- [19] Liska MG, Crowley MG, Borlongan CV. Regulated and unregulated clinical trials of stem cell therapies for stroke. *Transl Stroke Res.* 2017;8(2):93-103.
- [20] Merimi M, El-Majzoub R, Lagneaux L, Moussa Agha D, Bouhtit F, Meuleman N, et al. The therapeutic potential of mesenchymal stromal cells for regenerative medicine: Current knowledge and future understandings. *Front Cell Dev Biol.* 2021;9:661532.
- [21] Faden VB, Day NL, Windle M, Windle R, Grube JW, Molina BS, et al. Collecting longitudinal data through childhood, adolescence, and young adulthood: methodological challenges. *Alcohol Clin Exp Res.* 2004;28(2):330-40.
- [22] Burlacu A. Tracking the mesenchymal stem cell fate after transplantation into the infarcted myocardium. *Curr Stem Cell Res Ther.* 2013;8(4):284-91.
- [23] Jovic D, Yu Y, Wang D, Wang K, Li H, Xu F, et al. A brief overview of global trends in MSC-based cell therapy. *Stem Cell Rev Rep.* 2022;18(5):1525-45.
- [24] Wu Y, Shum HCE, Wu K, Vadgama J. From interaction to intervention: How mesenchymal stem cells affect and target triple-negative breast cancer. *Biomedicines.* 2023;11(4).
- [25] Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. *Front Immunol.* 2019;10:1191.
- [26] Nowzari F, Wang H, Khoradmehr A, Baghban M, Baghban N, Arandian A, et al. Three-dimensional imaging in stem cell-based researches. *Front Vet Sci.* 2021;8:657525.
- [27] Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: A fundamental biosafety aspect. *Int J Mol Sci.* 2019;20(10).
- [28] Omole AE, Fakoya AOJ, Nnawuba KC, Haider KH. Common ethical considerations of human-induced pluripotent stem cell research. *Handbook of Stem Cell Therapy: Springer; 2022.* p. 1-17.
- [29] Rubeis G, Steger F. Risks and benefits of human germline genome editing: An ethical analysis. *Asian Bioeth Rev.* 2018;10(2):133-41.
- [30] Kadam RA. Informed consent process: A step further towards making it meaningful! *Perspect Clin Res.* 2017;8(3):107-12.
- [31] Mehta P, Zimba O, Gasparyan AY, Seil B, Yessirkepov M. Ethics committees: Structure, roles, and issues. *J Korean Med Sci.* 2023;38(25):e198.
- [32] Cocuzza M, Alvarenga C, Pagani R. The epidemiology and etiology of azoospermia. *Clinics (Sao Paulo).* 2013;68 Suppl 1(Suppl 1):15-26.
- [33] Dunn CM, Kameishi S, Grainger DW, Okano T. Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies. *Acta Biomater.* 2021;133:114-25.

- [34] Lira FNTN. Hormonal treatment for men with non-obstructive azoospermia: Too many rationales, too little data. *Int Braz J Urol.* 2022;48(3):482-4.
- [35] Roshandel E, Mehravar M, Nikoonezhad M, Alizadeh AM, Majidi M, Salimi M, et al. Cell-based therapy approaches in treatment of non-obstructive azoospermia. *Reprod Sci.* 2023;30(5):1482-94.
- [36] Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. *J Hematol Oncol.* 2021;14(1):24.
- [37] Hsiao CH, Ji AT, Chang CC, Cheng CJ, Lee LM, Ho JH. Local injection of mesenchymal stem cells protects testicular torsion-induced germ cell injury. *Stem Cell Res Ther.* 2015;6(1):113.
- [38] Khatami F, Hassanzad M, Nikfar S, Guitynavard F, Karimae S, Tamehri Zadeh SS, et al. The importance of personalized medicine in urological cancers. *J Diabetes Metab Disord.* 2022;21(1):841-52.
- [39] Andrade DL, Viana MC, Esteves SC. Differential diagnosis of azoospermia in men with infertility. *J Clin Med.* 2021;10(14):3144.
- [40] Patel SA, King CC, Lim PK, Habiba U, Dave M, Porecha R, et al. Personalizing stem cell research and therapy: The arduous road ahead or missed opportunity? *Curr Pharmacogenomics Person Med.* 2010;8(1):25-36.
- [41] Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making and behavior change to promote prevention. *Stud Health Technol Inform.* 2017;240:284-302.